Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Compile Emergency Proposal for Economic Security in Early November
October 27, 2021
- Health Minister Vows Early Approval of Oral COVID-19 Drugs
October 27, 2021
- Industry Calls for Simplifying Regulatory Process for SaMD
October 26, 2021
- Lilly’s Migraine Drug Lasmiditan, Jardiance’s Heart Failure Use Up for PAFSC Review on Nov. 5
October 26, 2021
- PMDA Issues Guidance on COVID-19 Vaccines’ Immunogenicity Assessment for Non-Placebo-Controlled Trials
October 25, 2021
- MHLW Panels Continue to See No Major Safety Concerns for COVID-19 Jabs
October 25, 2021
- MHLW Proposes Further Measures to Promote Generics in Basic Plan for FY2022 Reimbursement Reform
October 25, 2021
- MHLW Panel OKs 81 More COVID-19 Vaccine Health Damage Claims
October 25, 2021
- Tecentriq under PMDA Safety Review for Cholangitis Sclerosing
October 25, 2021
- Herceptin’s Salivary Cancer Use Up for PAFSC Review on Nov. 4; Label Expansions for I/O Drugs, Lorbrena on Agenda Too
October 22, 2021
- Chuikyo Discusses Spillover Rules in Market Expansion Re-Pricing, PMP Criteria towards FY2022 Reform
October 21, 2021
- MHLW Health Service Chief Wants Prompt Debate on HPV Recommendation
October 20, 2021
- Average Price Gap for FY2022 Revision Likely to Be 8% Level or Lower: Wholesalers
October 20, 2021
- Japan to Boost Budgets for Vaccine Development and Supply: Govt Official
October 19, 2021
- Govt to Deliver 4.12 Million Comirnaty Doses for COVID-19 Boosters: Minister
October 19, 2021
- Discussions on Health Crisis Management Agency Comes after COVID-19 Master Plan: Minister
October 18, 2021
- Japan Govt Unveils Outline of COVID-19 Responses, Eyes Oral Drug Rollout by Year-End
October 18, 2021
- Chuikyo OKs MHLW Proposal on CEA Price Adjustments, Analysis Team Set-Up
October 18, 2021
- COVID-19 Vaccine Label Revised to Warn of Myocarditis Risk in Young Men
October 18, 2021
- MHLW’s Unapproved Drug Council Determines High Needs for 7 Additional Indications for Fertility Treatments
October 14, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…